(Q33349163)

26 July 2017

title

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies (English)

1 reference

26 July 2017

1 reference

1 reference

Paula M Fracasso

1

1 reference

26 July 2017

Luis C Rodriguez

2

1 reference

26 July 2017

Thomas J Herzog

3

1 reference

26 July 2017

Carole L Fears

4

1 reference

26 July 2017

Sherry A Goodner

5

1 reference

26 July 2017

Ramaswamy Govindan

6

1 reference

26 July 2017

Joel Picus

7

1 reference

26 July 2017

Janet S Rader

8

1 reference

26 July 2017

Benjamin R Tan

9

1 reference

26 July 2017

Matthew A Arquette

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

98

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

610-617

1 reference

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.11547

1 reference

7 January 2021

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

Drug interactions with the taxanes: clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11547

7 January 2021

Identifiers

DOI

10.1002/CNCR.11547

1 reference

26 July 2017

1 reference